5 research outputs found
Recurrence of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin G Deposits with a Striated Ultrastructure
This is the peer-reviewed but unedited manuscript version of the following article: Nephron 2020;144(suppl 1):43–48 (DOI: 10.1159/000512330)]. The final, published version is available at http://www.karger.com/?doi=10.1159/000512330
化学療法が著効を示した膀胱小細胞癌の1例
膀胱に発生する未分化癌は膀胱腫瘍の約1.2%といわれており, そのうち小細胞癌の頻度は極めて稀である.今回, われわれは, 膀胱小細胞癌の1例を経験したので, 治療を含め若干の文献的考察を加えて報告する.A 67-year-old man presented with asymptomatic gross hematuria. Cystoscopy and radiographic studies revealed a large tumor on the left lateral wall of the urinary bladder. Also, computer tomographic (CT) scan of the pelvic cavity showed metastasis to the left external iliac node. The light microscopic appearance of cold punch biopsy specimens for the tumor was closely akin to small cell carcinoma of the lung. Ultrastructurally, the tumor cells exhibited small numbers of neurosecretory granules in the cytoplasm. After surgical treatment, the patient was treated with combined chemotherapy using cis-diamminedichloroplatinum (CDDP) and etoposide. On CT scan, a remarkable remission was shown to have been induced at the metastatic site after three cycles of the therapy. Though the morphology of bladder tumors has not received very much attention, this report emphasizes that detailed pathological examination is of therapeutic importance
Recommended from our members
Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study
Poor post-vaccination production of antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a concern among solid organ transplant (SOT) recipients. Furthermore, the timing and kinetics of antibody titers after the second vaccine dose are unknown. We conducted a multicenter prospective observational study that included 614 SOT recipients: 460 kidney, 53 heart, 50 liver, 20 lung, and 31 simultaneous pancreas–kidney (SPK). The participants received two doses of the mRNA vaccine (Pfizer BNT162b2 or Moderna mRNA-1273), as indicated. Serum samples were collected before the first and second vaccinations and at 1, 3, and 6 months after the second vaccine dose, which were then assessed for SARS-CoV-2 antibodies. The overall seropositivity rate was 43% at 1 month after administration of the second vaccine dose; it gradually increased to 68% at 3 months after second dose administration and to 70% at 6 months. In addition, recipient of kidney, lung or SPK transplants had lower antibody titers at the 3- and 6-month time points than did the other recipients. SOT recipients acquired SARS-CoV-2 S-IgG antibodies slowly, and the peak titer differed significantly from that of the general population.
•Solid organ transplant recipients acquired SARS-CoV-2 antibodies slowly after vaccination